{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:15:47Z","timestamp":1790140547058,"version":"4.0.1"},"reference-count":48,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>\n                    FDA approved remdesivir, which was though very effective against SARS-corona virus in cell culture system but in human its efficacy was below 10%, as reported. The main reasons are due to the poor stability of remdesivir in presence plasma. In order to increase the protective strength of remdesivir we took couple of approaches, one, to make an alternative but better derivative of remdesivir as remdesivir bis-propionate, and the other is to use our platform- designed biopolymer (NV387) to protect remdesivir compound from degradation in presence of plasma. Here we present our results as: (1) Remdesivir-bP is much more stable\n                    <jats:italic>in vivo<\/jats:italic>\n                    compared to remdesivir alone. (2) Remdesivir-bP when encapsulated within biopolymer, NV387, its stability is further enhanced. (3) The antiviral activity is also increased against NL-63 infection to rat model, compared to naked and\/or encapsulated remdesivir. (4) The antiviral efficacy of the remdesivir pro-drug, therefore, can be mathematically drawn as follows: remdesivir-bP-encapsulated\u2009&gt;\u2009remdesivir-encapsulated\u2009&gt;\u2009remdesivir-bP\u2009&gt;\u2009remdesivir.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0324811","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T18:48:09Z","timestamp":1771613289000},"page":"e0324811","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Remdesivir-bisPropionate, a better derivative of remdesivir against SARS-CoV-2: Comparison of in vitro and in vivo PK\/PD Study as well as its therapeutic potential"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0232-3036","authenticated-orcid":true,"given":"Ashok","family":"Chakraborty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Diwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijetha","family":"Chiniga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogesh","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayant","family":"Tatake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preetam","family":"Holkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelam","family":"Holkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"key":"pone.0324811.ref001","doi-asserted-by":"crossref","DOI":"10.1177\/1076029619887437","article-title":"Acute Respiratory Distress Syndrome as an Organ Phenotype of Vascular Microthrombotic Disease: Based on Hemostatic Theory and Endothelial Molecular Pathogenesis","volume":"25","author":"JC Chang","year":"2019","journal-title":"Clin Appl Thromb Hemost"},{"issue":"6","key":"pone.0324811.ref002","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1007\/s43440-022-00425-5","article-title":"Recent review of COVID-19 management: diagnosis, treatment and vaccination","volume":"74","author":"VP Chavda","year":"2022","journal-title":"Pharmacol Rep"},{"issue":"8","key":"pone.0324811.ref003","doi-asserted-by":"crossref","first-page":"101648","DOI":"10.1016\/j.jksus.2021.101648","article-title":"SARS-CoV-2 spike protein: Site-specific breakpoints for the development of COVID-19 vaccines","volume":"33","author":"P Velusamy","year":"2021","journal-title":"J King Saud Univ Sci"},{"issue":"1","key":"pone.0324811.ref004","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12964-023-01104-5","article-title":"Structural and non-structural proteins in SARS-CoV-2: potential aspects to COVID-19 treatment or prevention of progression of related diseases","volume":"21","author":"S Kakavandi","year":"2023","journal-title":"Cell Commun Signal"},{"key":"pone.0324811.ref005","doi-asserted-by":"crossref","first-page":"113889","DOI":"10.1016\/j.biopha.2022.113889","article-title":"The role of SARS-CoV-2 accessory proteins in immune evasion","volume":"156","author":"M Zandi","year":"2022","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"pone.0324811.ref006","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.antiviral.2004.10.001","article-title":"Characterization of viral proteins encoded by the SARS-coronavirus genome","volume":"65","author":"Y-J Tan","year":"2005","journal-title":"Antiviral Res"},{"key":"pone.0324811.ref007","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bbrc.2020.08.116","article-title":"RNA-dependent RNA polymerase: Structure, mechanism, and drug discovery for COVID-19","volume":"538","author":"Y Jiang","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"pone.0324811.ref008","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41580-021-00432-z","article-title":"Structures and functions of coronavirus replication-transcription complexes and their relevance for SARS-CoV-2 drug design","volume":"23","author":"B Malone","year":"2022","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"11","key":"pone.0324811.ref009","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.3390\/v15112234","article-title":"The Application of Prodrugs as a Tool to Enhance the Properties of Nucleoside Reverse Transcriptase Inhibitors","volume":"15","author":"R Fernandes L da","year":"2023","journal-title":"Viruses"},{"issue":"6","key":"pone.0324811.ref010","first-page":"20","article-title":"The potential of remdesivir against sars COV 2: a review","volume":"12","author":"B Vinod","journal-title":"Int J Curr Pharm Res"},{"issue":"3","key":"pone.0324811.ref011","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2021.e06435","article-title":"Structural analogues of existing anti-viral drugs inhibit SARS-CoV-2 RNA dependent RNA polymerase: A computational hierarchical investigation","volume":"7","author":"MK Hasan","year":"2021","journal-title":"Heliyon"},{"issue":"1","key":"pone.0324811.ref012","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/med.21728","article-title":"COVID-19 drug repurposing: A review of computational screening methods, clinical trials, and protein interaction assays","volume":"41","author":"X Wang","year":"2021","journal-title":"Med Res Rev"},{"key":"pone.0324811.ref013","doi-asserted-by":"crossref","unstructured":"Hashemian SM, Farhadi T, Velayati AA. A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19. Drug Des Devel Ther. 2020 Aug 6; 14:321522.","DOI":"10.2147\/DDDT.S261154"},{"key":"pone.0324811.ref014","author":"National Center for Biotechnology Information"},{"key":"pone.0324811.ref015","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/128_2014_561","article-title":"Prodrugs of phosphonates and phosphates: crossing the membrane barrier","volume":"360","author":"AJ Wiemer","year":"2015","journal-title":"Top Curr Chem"},{"key":"pone.0324811.ref016","first-page":"44407","article-title":"Federal Register","volume":"87","year":"2022","journal-title":"Federal Register"},{"issue":"20","key":"pone.0324811.ref017","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1074\/jbc.RA120.013679","article-title":"Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency","volume":"295","author":"CJ Gordon","year":"2020","journal-title":"J Biol Chem"},{"key":"pone.0324811.ref018","doi-asserted-by":"crossref","first-page":"115279","DOI":"10.1016\/j.bcp.2022.115279","article-title":"An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challenges","volume":"205","author":"X Xu","year":"2022","journal-title":"Biochem Pharmacol"},{"issue":"8","key":"pone.0324811.ref019","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2021.e07666","article-title":"Abbreviated Profile of Drugs (APOD): modeling drug safety profiles to prioritize investigational COVID-19 treatments","volume":"7","author":"CN Hiremath","year":"2021","journal-title":"Heliyon"},{"issue":"8","key":"pone.0324811.ref020","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.jiph.2021.06.013","article-title":"Trends in the development of remdesivir based inventions against COVID-19 and other disorders: A patent review","volume":"14","author":"M Imran","year":"2021","journal-title":"J Infect Public Health"},{"issue":"5","key":"pone.0324811.ref021","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s40262-021-00984-5","article-title":"Pharmacokinetic, pharmacodynamic, and drug-interaction profile of remdesivir, a SARS-CoV-2 replication inhibitor","volume":"60","author":"R Humeniuk","year":"2021","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"pone.0324811.ref022","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00254-22","article-title":"Population pharmacokinetics of remdesivir and GS-441524 in hospitalized COVID-19 patients","volume":"66","author":"E Leegwater","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"pone.0324811.ref023","article-title":"Captisol and GS-704277, but not GS-441524, Are Credible Mediators of Remdesivir\u2019s Nephrotoxicity","volume":"64","author":"VC Yan","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"6498","key":"pone.0324811.ref024","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1126\/science.abc1560","article-title":"Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir","volume":"368","author":"W Yin","year":"2020","journal-title":"Science"},{"issue":"7","key":"pone.0324811.ref025","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1021\/acsmedchemlett.0c00316","article-title":"Advantages of the parent nucleoside GS-441524 over remdesivir for Covid-19 treatment","volume":"11","author":"VC Yan","year":"2020","journal-title":"ACS Med Chem Lett"},{"issue":"4","key":"pone.0324811.ref026","doi-asserted-by":"crossref","first-page":"72","DOI":"10.4331\/wjbc.v14.i4.72","article-title":"In silico evidence of Remdesivir action in blood coagulation cascade modulation in COVID-19 treatment","volume":"14","author":"LG Pagliarin","year":"2023","journal-title":"World J Biol Chem"},{"issue":"3","key":"pone.0324811.ref027","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.ekir.2020.11.025","article-title":"Remdesivir in Patients With Estimated GFR <30\u2009ml\/min per 1.73 m2 or on renal replacement therapy","volume":"6","author":"C Estiverne","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"11","key":"pone.0324811.ref028","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.3390\/healthcare10112299","article-title":"Safety Evaluation of Remdesivir for COVID-19 Patients with eGFR < 30\u2009mL\/min without Renal Replacement Therapy in a Japanese Single-Center Study","volume":"10","author":"T Umemura","year":"2022","journal-title":"Healthcare (Basel)"},{"key":"pone.0324811.ref029","unstructured":"Remdesivir (Veklury) [package insert]. Food and Drug Administration. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/214787s019lbl.pdf"},{"issue":"2","key":"pone.0324811.ref030","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2174\/157340312801784961","article-title":"Utility of the electrocardiogram in drug overdose and poisoning: theoretical considerations and clinical implications","volume":"8","author":"C Yates","year":"2012","journal-title":"Curr Cardiol Rev"},{"issue":"12","key":"pone.0324811.ref031","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0278963","article-title":"Dual effects of NV-CoV-2 biomimetic polymer: An antiviral regimen against COVID-19","volume":"17","author":"A Chakraborty","year":"2022","journal-title":"PLoS One"},{"issue":"8","key":"pone.0324811.ref032","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0020240","article-title":"Croup is associated with the novel coronavirus NL63","volume":"2","author":"L van der Hoek","year":"2005","journal-title":"PLoS Med"},{"issue":"6965","key":"pone.0324811.ref033","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus","volume":"426","author":"W Li","year":"2003","journal-title":"Nature"},{"key":"pone.0324811.ref034","first-page":"805","article-title":"Coronavirus infections in working adults. Eight-year study with 229 E and OC 43","volume":"105","author":"JO Hendley","year":"1972","journal-title":"Am Rev Respir Dis"},{"key":"pone.0324811.ref035","doi-asserted-by":"crossref","first-page":"113201","DOI":"10.1016\/j.ejmech.2021.113201","article-title":"RNA-dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID-19 pandemic","volume":"213","author":"L Tian","year":"2021","journal-title":"Eur J Med Chem"},{"issue":"4","key":"pone.0324811.ref036","doi-asserted-by":"crossref","DOI":"10.23880\/MJCCS-16000298","article-title":"Broad Spectrum Antiviral Therapy can Supersede Vaccination Strategy for Combating COVID-19 Pandemic","volume":"5","author":"A Chakraborty","year":"2021","journal-title":"Med J Clin Trials Case Stud"},{"issue":"10","key":"pone.0324811.ref037","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1016\/j.xphs.2022.06.004","article-title":"Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19 Treatment","volume":"111","author":"G Sahin","year":"2022","journal-title":"J Pharm Sci"},{"key":"pone.0324811.ref038","doi-asserted-by":"crossref","first-page":"102170","DOI":"10.1016\/j.pupt.2022.102170","article-title":"Treatment of respiratory viral infections through inhalation therapeutics: Challenges and opportunities","volume":"77","author":"N Nainwal","year":"2022","journal-title":"Pulm Pharmacol Ther"},{"issue":"11","key":"pone.0324811.ref039","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1111\/bph.15418","article-title":"Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro","volume":"178","author":"S Schloer","year":"2021","journal-title":"Br J Pharmacol"},{"issue":"1","key":"pone.0324811.ref040","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202013105","article-title":"A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2","volume":"13","author":"A Simonis","year":"2021","journal-title":"EMBO Mol Med"},{"issue":"7","key":"pone.0324811.ref041","doi-asserted-by":"crossref","first-page":"941","DOI":"10.3390\/antibiotics11070941","article-title":"Co-Administration of remdesivir and azithromycin may protect against intensive care unit admission in COVID-19 pneumonia requiring hospitalization: a real-life observational study","volume":"11","author":"A Ticinesi","year":"2022","journal-title":"Antibiotics (Basel)"},{"issue":"13","key":"pone.0324811.ref042","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1080\/07391102.2020.1781694","article-title":"Remdesivir (GS-5734) as a therapeutic option of 2019-nCOV main protease - in silico approach","volume":"39","author":"VR Naik","year":"2021","journal-title":"J Biomol Struct Dyn"},{"key":"pone.0324811.ref043","doi-asserted-by":"crossref","first-page":"830990","DOI":"10.3389\/fimmu.2022.830990","article-title":"Remdesivir and its combination with repurposed drugs as COVID-19 therapeutics","volume":"13","author":"B Chatterjee","year":"2022","journal-title":"Front Immunol"},{"issue":"19","key":"pone.0324811.ref044","doi-asserted-by":"crossref","first-page":"5905","DOI":"10.3390\/molecules26195905","article-title":"Controlled drug delivery systems: Current Status and Future Directions","volume":"26","author":"S Adepu","year":"2021","journal-title":"Molecules"},{"key":"pone.0324811.ref045","article-title":"US Update: Double Patenting","author":"A Bhattacharyya","year":"2019","journal-title":"CIPA J"},{"issue":"4","key":"pone.0324811.ref046","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s13205-022-03151-0","article-title":"Insights into the structure and dynamics of SARS-CoV-2 spike glycoprotein double mutant L452R-E484Q","volume":"12","author":"S Ahamad","year":"2022","journal-title":"3 Biotech"},{"issue":"5","key":"pone.0324811.ref047","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1080\/07391102.2021.2024449","article-title":"Lead optimization, pharmacophore development and scaffold design of protein kinase CK2 inhibitors as potential COVID-19 therapeutics","volume":"41","author":"S Yadav","year":"2023","journal-title":"J Biomol Struct Dyn"},{"issue":"3","key":"pone.0324811.ref048","first-page":"13","article-title":"Anti-fungal drug anidulafungin inhibits SARS-CoV-2 spike-induced syncytia formation by targeting ACE2-spike protein interaction","volume":"25","author":"S Ahamad","year":"2022","journal-title":"Front Genet"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0359020","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000}}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0324811","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T18:48:18Z","timestamp":1771613298000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0324811"}},"subtitle":[],"editor":[{"given":"Tamer M.","family":"Ibrahim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":48,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0324811","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]}}}